♥ HF Guideline NavigatorESC 2026

3 › 3.2

3.2 Epidemiology of heart failure

Pages 15–16 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 15 · PDF

In cases of a clear association between paroxysmal or persistent AF and worsening of HF symptoms, which persist despite MT, catheter ablation should be considered for the prevention or treatment of AF.

Catheter ablation for AF should be considered in IIa

angina, despite FMT for HF and antianginal drugs, to relieve symptoms.

antianginal drugs. Aortic valve intervention, TAVI or SAVR, is

Aortic valve intervention, SAVR or TAVI, is

recommended in patients with HF and severe

recommended in patients with severe aortic

high-gradient aortic stenosis to reduce mortality and improve symptoms.

Percutaneous edge-to-edge mitral valve repair should be considered in carefully selected patients

Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable,

with secondary mitral regurgitation, not eligible for surgery and not needing coronary revascularization, who are symptomatic despite

stenosis and HF to improve symptoms and reduce the risk of death.

symptomatic patients with HFrEF and persistent IIa

severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil

OMT and who fulfil criteria for achieving a

specific clinical and echocardiographic criteria, in

reduction in HF hospitalizations.

order to reduce the risk of HFH and improve QoL.

Multidisciplinary management—Section 11 Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF in order to improve clinical outcomes.

Remote haemodynamic monitoring of PA pressure IIb

should be considered in symptomatic patients with HF, NYHA class III and an HFH in the past 12 months in order to reduce the risk of HFH.

Specific conditions—Section 12

or II symptoms to reduce symptoms, CV

hospitalization and mortality.

variant or wild-type transthyretin cardiac amyloidosis and NYHA class I–III is recommended to reduce progression of symptoms and the risk of

Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and

Treatment with a TTR silencer (vutrisiran) or stabilizer (tafamidis or acoramidis) for patients with

CV hospitalization and all-cause death.

mortality. ACE-I angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARNI, angiotensin receptor–neprilysin inhibitor; AV, atrioventricular; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; CAD, coronary artery disease; CCS, chronic coronary syndrome; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CV, cardiovascular; DCM, dilated cardiomyopathy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hTTR-CA, hereditary transthyretin cardiac amyloidosis; IABP, intra-aortic balloon pump; LGE, late gadolinium enhancement; LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; MT, medical therapy; nsMRA, non-steroidal mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OMT, optimal medical therapy; PA, pulmonary artery; QoL, quality of life; RV, right ventricular; SAVR, surgical aortic valve replacement; sMRA, steroidal mineralocorticoid receptor antagonist; TAVI, transcatheter aortic valve implantation; TTR, transthyretin; wtTTR-CA, wild-type transthyretin cardiac amyloidosis. a Class of recommendation. b Level of evidence.

3. Definition, epidemiology, and classifications 3.1. Definition of heart failure Heart failure is a clinical syndrome comprising signs and/or symptoms caused by structural and/or functional abnormalities of the heart that result in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise.11 In addition to the subjective symptoms of HF, clinically assessed objective evidence of cardiogenic pulmonary and/or systemic congestion and diagnostic supportive tests are needed to reach the diagnosis (see Section 5).11

People who are in asymptomatic stages are not included under the above definition as having HF. They are defined as being at risk for HF (stage A) or having pre-HF (stage B) (see Section 3.3). Identification of the aetiology of the underlying cardiac dysfunction is not included in the definition of HF, although determining aetiology is clinically important as the specific pathology can determine subsequent treatment and prognosis. Specific investigations needed to identify underlying aetiologies are described in Section 5.

3.2. Epidemiology of heart failure The prevalence of HF is estimated to be 1%–3% in the general adult population, with significant geographical, age- and sex-related

Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I

and coronary anatomy suitable for revascularization, despite OMT including

to improve QoL and reduce the risk of HFH or death. Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent

Coronary revascularization should be considered to relieve persistent symptoms of angina (or an angina-equivalent) in patients with HFrEF, CCS,

selected patients with symptomatic AF and HFrEF

Page 16 · PDF

3.2.1. Epidemiology of heart failure phenotypes In population-based samples, nearly half of all HF cases have HF with preserved ejection fraction (HFpEF), and this proportion may be increasing due to better treatment of coronary artery disease (CAD) and the rising burden of hypertension, obesity, and other HFpEF risk factors.21 Patients with HFpEF are older and are more often female. The Swedish HF registry reported an average age at HFpEF onset of 77 years with 55% female.22 In patients with heart failure with reduced ejection fraction (HFrEF), 71% were male and the mean age at onset was 72 years.22 Several subtypes of HFpEF have been suggested, with up to 50% of patients having a predominantly metabolic/obesity subtype [younger, higher body mass index (BMI)] in some regions, and up to 50% with a predominantly ageing, vascular subtype [older, stiff arteries, high prevalence of chronic kidney disease (CKD)] in other regions.23,24 Heart failure with reduced ejection fraction is often subdivided into ischaemic vs non-ischaemic aetiologies, with approximately half of all cases being considered ischaemic.

3.2.2. Natural history and prognosis Although the mortality rates after HF onset have improved considerably over the past three decades, the 5-year overall survival rates are still <60%.25,26 For younger patients, data from Denmark suggest survival has improved with contemporary management, with a current 5-year mortality rate of 15% for patients <65 years and 39% for patients aged 65–79 years.25 In patients ≥80 years, improvements in mortality have also been observed, although these improvements are not as pronounced as those observed in younger patients, partly due to a greater burden of comorbidity and a greater proportion of non-CV mortality in the elderly.17,25,27 Mortality may be lower in HFpEF than HFrEF, but overall differences are small as patients with HFpEF are considerably older, and the risk of hospitalization is similar.28,29 Patients diagnosed with HF in an outpatient setting have better

prognosis than patients diagnosed during a HFH, and patients with repeated HFH have a particularly high risk of mortality.30,31 The overall burden of HF as well as HFH can be expected to rise over the next few decades due to greater survival, an ageing population, and greater prevalence of risk factors and obesity in the younger population.

3.3. Classifications 3.3.1. Classification based on left ventricular ejection fraction Traditionally, HF has been divided into distinct phenotypes based on the measurement of LVEF. In the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, three different HF phenotypes were identified: HFrEF (LVEF ≤40%); HF with mildly reduced ejection fraction (HFmrEF, LVEF 41%–49%); and HFpEF (LVEF ≥50%).3 The rationale behind this classification relates to the inclusion criteria of the trials of therapies that improved outcomes in patients with HF and LVEF ≤40%. The HFmrEF phenotype was introduced to focus on patients usually not included in HFrEF trials. The nomenclature was changed from ‘mid-range’ to ‘mildly reduced’ to highlight that patients with HFmrEF are similar to patients with HFrEF in terms of both clinical characteristics, outcomes, and response to treatments.32,33 Patients with HFmrEF have similar underlying aetiology of HF to patients with HFrEF, and the pathophysiology of HFmrEF is more similar to HFrEF (reduced contractility and systolic dysfunction) than HFpEF (increased stiffness and diastolic dysfunction).34 In addition, the efficacy of medical treatment of HFmrEF is more similar to HFrEF than HFpEF.35–45 Finally, it is important to consider LVEF trajectories, as many patients with LVEF 41%–49% may experience a deterioration in LVEF.46 The Task Force for the 2026 ESC Guidelines for the management of heart failure has eliminated the phenotype of HFmrEF and reclassified HF based on a pathophysiological classification of HF, including two distinct phenotypes: (i) HFrEF: characterized by LVEF <50% and symptoms and/or signs of HF. (ii) HFpEF: characterized by LVEF ≥50% and symptoms and/or signs of HF and objective evidence of cardiac structural and/ or functional abnormalities consistent with the presence of left ventricular (LV) diastolic dysfunction/raised LV filling pressures, supported by raised natriuretic peptides. Using a single LVEF value as cut-point for distinguishing HFpEF and HFrEF is somewhat arbitrary and has to be evaluated in the clinical situation, as there is variability in measurement depending both on the modality and the interpreter. Furthermore, LVEF may be falsely high in certain situations, e.g. mitral regurgitation (MR). Natriuretic peptides may be used as supportive evidence for the diagnosis of HF. Importantly, drug and device therapies can lead to positive LV reverse remodelling in patients with HFrEF and, thus, improvement of LVEF. Patients with HFrEF and improved LVEF have a more favourable prognosis. However, it is important to ensure that these patients are still managed with optimal medical therapy except for selected patients. The current definition of improved LVEF requires an increase of at least 10% in LVEF (absolute) and must be at least above 40% (often normal).47

variations.12,13 Both the incidence and prevalence of HF are increasing with age and risk-factor burden, with wide variation depending on the population and setting studied and the diagnostic criteria used.14 In addition, several factors, such as level of education, income, neighbourhood deprivation, climate, and air pollution, influence the risk of HF, contributing to varying epidemiology worldwide.13 In European countries, current prevalance-estimates range from 12–58 cases per 1000 people.15 As a result of the growing cohort of older people in Western populations, the crude incidence of HF has been increasing and is currently 2–13 per 1000 person-years in Europe (ranging from <1 per 1000 person-years for people aged 45–54 years to >12 per 1000 person-years for people aged >74 years).16,17 However, age-adjusted HF incidence rates have been declining over the past three decades, probably because of better risk-factor control and treatment of CV conditions.15,17,18 Among younger adults, incidence rates of HF appear to be either increasing or stagnating. There are several possible explanations for this, including (i) a greater burden of CV risk factors, (ii) increasing numbers of patients with congenital heart disease reaching adulthood, and (iii) a change in surveillance patterns.16,19,20 Furthermore, the mortality of HF has improved, which has led to a higher prevalence of HF.13